Compare · LLY vs TLPH
LLY vs TLPH
Side-by-side comparison of Eli Lilly and Company (LLY) and Talphera Inc. (TLPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and TLPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.12T, about 14772.1x TLPH ($75.8M).
- Over the past year, LLY is up 48.8% and TLPH is up 209.0% - TLPH leads by 160.3 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- LLY has more recent analyst coverage (25 ratings vs 2 for TLPH).
- Company
- Eli Lilly and Company
- Talphera Inc.
- Price
- $1188.57-2.23%
- $1.45+7.01%
- Market cap
- $1.12T
- $75.8M
- 1M return
- +3.90%
- +77.26%
- 1Y return
- +48.77%
- +209.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 2
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)
Latest TLPH
- Director Wan Mark A was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Todisco Joseph was granted 5,100 shares, increasing direct ownership by 80% to 11,497 units (SEC Form 4)
- Director Jain Abhinav was granted 5,100 shares, increasing direct ownership by 70% to 12,412 units (SEC Form 4)
- Director Hoffman Stephen J was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Broadfoot Jill Marie was granted 5,100 shares, increasing direct ownership by 60% to 13,647 units (SEC Form 4)
- Director Bozilenko Marina was granted 5,100 shares, increasing direct ownership by 56% to 14,147 units (SEC Form 4)
- Director Adams Adrian was granted 5,100 shares, increasing direct ownership by 29% to 22,709 units (SEC Form 4)
- Talphera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- H.C. Wainwright resumed coverage on Talphera with a new price target
- Chief Medical Officer Aslam Shakil covered exercise/tax liability with 4,518 shares, decreasing direct ownership by 6% to 76,542 units (SEC Form 4) to cover taxes